Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01295463
First received: February 11, 2011
Last updated: August 9, 2013
Last verified: February 2011
History of Changes
  Purpose

RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.

PURPOSE: This clinical trial is studying the amount of information on fertility and infertility received by patients before treatment of cancer in patients who have finished treatment.


Condition Intervention
Cancer
 Other: questionnaire administration
Other: study of socioeconomic and demographic variables
Procedure: assessment of therapy complications
Procedure: fertility assessment and management
Procedure: psychosocial assessment and care
Procedure: quality-of-life assessment

Study Type: Observational
Official Title: Descriptive Study to Evaluate the Information and Psychosocial Issues on the Risk on Infertility in Cancer Patients After Receiving Treatment in a Comprehensive Cancer Center

Resource links provided by NLM:

MedlinePlus related topics: Cancer Infertility
Genetic and Rare Diseases Information Center resources: Acute Lymphoblastic Leukemia Acute Monoblastic Leukemia Acute Myeloblastic Leukemia Type 5 Acute Myelocytic Leukemia Acute Myeloid Leukemia, Adult Acute Non Lymphoblastic Leukemia Anaplastic Large Cell Lymphoma Angioimmunoblastic Lymphadenopathy With Dysproteinemia Angioimmunoblastic T-cell Lymphoma Bone Cancer Breast Cancer, Male Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Chronic Myelomonocytic Leukemia Classic Kaposi Sarcoma Hairy Cell Leukemia Hodgkin Lymphoma Large Granular Lymphocyte Leukemia Leukemia, B-cell, Chronic Leukemia, Myeloid Leukemia, T-cell, Chronic Lymphoma, Large-cell Lymphosarcoma Malignant Mesenchymal Tumor Mycosis Fungoides Osteosarcoma Sezary Syndrome Soft Tissue Sarcoma Systemic Mastocytosis Uterine Sarcoma
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Amount of information received on aspects of fertility and infertility [ Designated as safety issue: No ]
  • Relationship between demographic data, diagnosis, quality of life, and associated psychosocial information received [ Designated as safety issue: No ]
Estimated Enrollment: 96
Study Start Date: December 2010
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • To determine the amount of information received on aspects of fertility and infertility in patients with cancer prior to receiving treatment in a comprehensive cancer center.

Secondary

  • To analyze whether the information received by patients is related to the desire to be parents.
  • To analyze whether the information received by patients is related to the desire to be informed.
  • To determine whether there is a relationship between demographic data, diagnosis, quality of life, and associated psychosocial information received by patients.

OUTLINE: Patients complete questionnaires (Lickert and QLQ-C30) on the amount of information received prior to therapy and psychosocial issues on aspects of fertility and infertility once within 1-2 years after receiving treatment.

  Eligibility
Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of breast cancer, germ cell tumor, colon cancer, leukemia, lymphoma, or sarcoma

    • Free of disease
  • Completed treatment within the past 1-2 years

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-1
  • Must be able to read and self-complete study questionnaires
  • No psychological conditions that may prevent participation in the study

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No concurrent treatment (hormonal treatment for breast cancer is allowed)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01295463

Locations
Spain
Institut Catala D'Oncologia Recruiting
l'Hospitalet de Llobregat, Spain, 08907
Contact: Josefina Rivera, RGN, MSN    34-93-260-7332    jrivera@iconcologia.net   
Sponsors and Collaborators
Institut Catala D'Oncologia
Investigators
Principal Investigator: Josefina Rivera, RGN, MSN Institut Catala D'Oncologia
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT01295463     History of Changes
Other Study ID Numbers: ICO-FERTI, CDR0000695000, EU-21105
Study First Received: February 11, 2011
Last Updated: August 9, 2013
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
Kaposi sarcoma
sexual dysfunction
psychosocial effects of cancer and its treatment
infertility
colon cancer
male breast cancer
breast cancer
germ cell tumor
ovarian sarcoma
uterine sarcoma
chronic lymphocytic leukemia
osteosarcoma
chronic myelogenous leukemia
non-Hodgkin lymphoma
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
 adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
mast cell leukemia
hairy cell leukemia
prolymphocytic leukemia
adult acute lymphoblastic leukemia
adult acute myeloid leukemia
adult Hodgkin lymphoma
adult T-cell leukemia/lymphoma
small intestine lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
mycosis fungoides/Sezary syndrome

ClinicalTrials.gov processed this record on March 01, 2015